D
Zevra Therapeutics, Inc.
ZVRA
$8.42
$0.486.05%
D
Sell
8/16/2024Upgraded
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D- from E+ on 8/16/2024 due to an increase in the volatility index, growth index and total return index. Total revenue increased 29.9% from $3.43M to $4.45M.
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D- from E+ on 8/16/2024 due to an increase in the volatility index, growth index and total return index. Total revenue increased 29.9% from $3.43M to $4.45M.
E
Sell
5/14/2024Downgrade
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D- on 5/14/2024 due to a decline in the growth index, valuation index and solvency index. Total revenue declined 74.09% from $13.22M to $3.43M, EBIT declined 39.64% from -$14.67M to -$20.49M, and debt to equity increased from 0.7 to 0.89.
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D- on 5/14/2024 due to a decline in the growth index, valuation index and solvency index. Total revenue declined 74.09% from $13.22M to $3.43M, EBIT declined 39.64% from -$14.67M to -$20.49M, and debt to equity increased from 0.7 to 0.89.
D
Sell
4/17/2024Downgrade
Zevra Therapeutics, Inc. (ZVRA) was downgraded to D- from D on 4/17/2024 due to a noticeable decline in the solvency index, volatility index and valuation index.
Zevra Therapeutics, Inc. (ZVRA) was downgraded to D- from D on 4/17/2024 due to a noticeable decline in the solvency index, volatility index and valuation index.
D
Sell
4/2/2024Upgraded
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D from D- on 4/2/2024 due to an increase in the volatility index, total return index and valuation index.
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D from D- on 4/2/2024 due to an increase in the volatility index, total return index and valuation index.
D
Sell
8/31/2023Upgraded
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index.
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index.
E
Sell
8/16/2023Downgrade
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D- on 8/16/2023 due to a decline in the total return index, volatility index and valuation index.
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D- on 8/16/2023 due to a decline in the total return index, volatility index and valuation index.
D
Sell
8/8/2023Upgraded
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D- from E+ on 8/8/2023 due to an increase in the volatility index.
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D- from E+ on 8/8/2023 due to an increase in the volatility index.
E
Sell
7/24/2023Downgrade
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D- on 7/24/2023 due to a decline in the volatility index and total return index.
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D- on 7/24/2023 due to a decline in the volatility index and total return index.
D
Sell
7/6/2023Upgraded
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index.
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index.
E
Sell
6/20/2023Downgrade
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D- on 6/20/2023 due to a noticeable decline in the growth index, volatility index and solvency index. EBIT declined 39.67% from -$9.25M to -$12.92M, earnings per share declined from -$0.2614 to -$0.3414, and debt to equity increased from 0.15 to 0.19.
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D- on 6/20/2023 due to a noticeable decline in the growth index, volatility index and solvency index. EBIT declined 39.67% from -$9.25M to -$12.92M, earnings per share declined from -$0.2614 to -$0.3414, and debt to equity increased from 0.15 to 0.19.
D
Sell
3/14/2023Downgrade
Zevra Therapeutics, Inc. (ZVRA) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index and solvency index. Debt to equity increased from 0.14 to 0.21, EBIT declined 39.65% from -$6.63M to -$9.25M, and earnings per share declined from -$0.1918 to -$0.2614.
Zevra Therapeutics, Inc. (ZVRA) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index and solvency index. Debt to equity increased from 0.14 to 0.21, EBIT declined 39.65% from -$6.63M to -$9.25M, and earnings per share declined from -$0.1918 to -$0.2614.
D
Sell
2/23/2023Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/14/2022Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 11/14/2022 due to a substantial increase in the growth index, volatility index and valuation index. Total revenue increased 121.08% from $1.3M to $2.87M, earnings per share increased from -$0.6979 to -$0.1918, and EBIT increased 6.73% from -$7.1M to -$6.63M.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 11/14/2022 due to a substantial increase in the growth index, volatility index and valuation index. Total revenue increased 121.08% from $1.3M to $2.87M, earnings per share increased from -$0.6979 to -$0.1918, and EBIT increased 6.73% from -$7.1M to -$6.63M.
D
Sell
8/15/2022Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 8/15/2022 due to a substantial decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.054 to -$0.6979, EBIT declined 282.14% from -$1.86M to -$7.1M, and total revenue declined 67.21% from $3.97M to $1.3M.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 8/15/2022 due to a substantial decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.054 to -$0.6979, EBIT declined 282.14% from -$1.86M to -$7.1M, and total revenue declined 67.21% from $3.97M to $1.3M.
D
Sell
5/16/2022Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and total return index.
KemPharm, Inc. (KMPH) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and total return index.
E
Sell
5/13/2022Downgrade
KemPharm, Inc. (KMPH) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
KemPharm, Inc. (KMPH) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D from E+ on 05/04/2022.
Zevra Therapeutics, Inc. (ZVRA) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D on 05/01/2022.
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
KemPharm, Inc. (KMPH) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
E
Sell
4/20/2022Downgrade
KemPharm, Inc. (KMPH) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 36 to 26.92.
KemPharm, Inc. (KMPH) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 36 to 26.92.
D
Sell
11/15/2021Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 11/15/2021 due to an increase in the total return index and volatility index.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 11/15/2021 due to an increase in the total return index and volatility index.
D
Sell
11/8/2021Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the total return index.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the total return index.
D
Sell
3/16/2021Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 3/16/2021 due to a major increase in the growth index, total return index and volatility index. Total revenue increased 22.91% from $1.93M to $2.37M.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 3/16/2021 due to a major increase in the growth index, total return index and volatility index. Total revenue increased 22.91% from $1.93M to $2.37M.
D
Sell
11/12/2020Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 11/12/2020 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0132 to -$0.0425, operating cash flow declined 147.93% from $2.19M to -$1.05M, and EBIT declined 146.78% from $2.59M to -$1.21M.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 11/12/2020 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0132 to -$0.0425, operating cash flow declined 147.93% from $2.19M to -$1.05M, and EBIT declined 146.78% from $2.59M to -$1.21M.
D
Sell
5/20/2020Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 5/20/2020 due to a significant increase in the growth index and volatility index. Total revenue increased 51.82% from $1.38M to $2.09M, operating cash flow increased 34.73% from -$3.1M to -$2.02M, and earnings per share increased from -$0.1813 to -$0.1197.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 5/20/2020 due to a significant increase in the growth index and volatility index. Total revenue increased 51.82% from $1.38M to $2.09M, operating cash flow increased 34.73% from -$3.1M to -$2.02M, and earnings per share increased from -$0.1813 to -$0.1197.
D
Sell
2/28/2020Upgraded
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 2/28/2020 due to an increase in the volatility index.
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 2/28/2020 due to an increase in the volatility index.
E
Sell
2/27/2020Downgrade
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 2/27/2020 due to a decline in the volatility index.
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 2/27/2020 due to a decline in the volatility index.
D
Sell
2/10/2020Upgraded
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 2/10/2020 due to an increase in the volatility index and valuation index.
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 2/10/2020 due to an increase in the volatility index and valuation index.
E
Sell
1/24/2020Downgrade
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 1/24/2020 due to a decline in the volatility index.
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 1/24/2020 due to a decline in the volatility index.
D
Sell
1/9/2020Upgraded
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 1/9/2020 due to an increase in the volatility index.
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 1/9/2020 due to an increase in the volatility index.
E
Sell
12/10/2019Downgrade
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 12/10/2019 due to a decline in the efficiency index, volatility index and total return index.
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 12/10/2019 due to a decline in the efficiency index, volatility index and total return index.
D
Sell
10/7/2019Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 10/7/2019 due to a decline in the total return index and volatility index.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 10/7/2019 due to a decline in the total return index and volatility index.
D
Sell
8/15/2019Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 8/15/2019 due to a large increase in the growth index, efficiency index and total return index. Operating cash flow increased 33.63% from -$11.07M to -$7.34M, EBIT increased 31.46% from -$11.37M to -$7.79M, and earnings per share increased from -$0.4603 to -$0.33.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 8/15/2019 due to a large increase in the growth index, efficiency index and total return index. Operating cash flow increased 33.63% from -$11.07M to -$7.34M, EBIT increased 31.46% from -$11.37M to -$7.79M, and earnings per share increased from -$0.4603 to -$0.33.
D
Sell
3/12/2019Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 3/12/2019 due to a substantial decline in the efficiency index, total return index and solvency index.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 3/12/2019 due to a substantial decline in the efficiency index, total return index and solvency index.
D
Sell
11/19/2018Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 11/19/2018 due to a significant increase in the efficiency index and valuation index.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 11/19/2018 due to a significant increase in the efficiency index and valuation index.
D
Sell
5/23/2018Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 5/23/2018 due to a decline in the growth index, total return index and efficiency index. Net income declined 148.14% from -$10.57M to -$26.22M, earnings per share declined from -$0.7209 to -$1.7725, and operating cash flow declined 103.27% from -$6.94M to -$14.1M.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 5/23/2018 due to a decline in the growth index, total return index and efficiency index. Net income declined 148.14% from -$10.57M to -$26.22M, earnings per share declined from -$0.7209 to -$1.7725, and operating cash flow declined 103.27% from -$6.94M to -$14.1M.
D
Sell
4/3/2018Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 4/3/2018 due to a major increase in the total return index, volatility index and growth index. Operating cash flow increased 31.8% from -$10.17M to -$6.94M, and EBIT increased 15.21% from -$9.61M to -$8.15M.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 4/3/2018 due to a major increase in the total return index, volatility index and growth index. Operating cash flow increased 31.8% from -$10.17M to -$6.94M, and EBIT increased 15.21% from -$9.61M to -$8.15M.
D
Sell
5/31/2017Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 5/31/2017 due to a significant decline in the efficiency index and growth index. Net income declined 64.27% from -$9.94M to -$16.32M, earnings per share declined from -$0.6784 to -$1.1144, and total capital declined 20.43% from $72.63M to $57.79M.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 5/31/2017 due to a significant decline in the efficiency index and growth index. Net income declined 64.27% from -$9.94M to -$16.32M, earnings per share declined from -$0.6784 to -$1.1144, and total capital declined 20.43% from $72.63M to $57.79M.
D
Sell
3/14/2017Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from E+ on 3/14/2017 due to a significant increase in the efficiency index and growth index. Net income increased 25.93% from -$13.41M to -$9.94M, and earnings per share increased from -$0.9158 to -$0.6784.
KemPharm, Inc. (KMPH) was upgraded to D from E+ on 3/14/2017 due to a significant increase in the efficiency index and growth index. Net income increased 25.93% from -$13.41M to -$9.94M, and earnings per share increased from -$0.9158 to -$0.6784.
E
Sell
8/1/2016Downgrade
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 8/1/2016 due to a decline in the total return index and volatility index.
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 8/1/2016 due to a decline in the total return index and volatility index.
D
Sell
7/11/2016Upgraded
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 7/11/2016 due to an increase in the volatility index.
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 7/11/2016 due to an increase in the volatility index.
E
Sell
6/14/2016Downgrade
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 6/14/2016 due to a large decline in the total return index, volatility index and efficiency index.
KemPharm, Inc. (KMPH) was downgraded to E+ from D- on 6/14/2016 due to a large decline in the total return index, volatility index and efficiency index.
D
Sell
5/13/2016Downgrade
KemPharm, Inc. (KMPH) was downgraded to D- from D on 5/13/2016 due to a noticeable decline in the volatility index, efficiency index and total return index.
KemPharm, Inc. (KMPH) was downgraded to D- from D on 5/13/2016 due to a noticeable decline in the volatility index, efficiency index and total return index.
D
Sell
5/2/2016Upgraded
KemPharm, Inc. (KMPH) was upgraded to D from D- on 5/2/2016 due to an increase in the total return index, efficiency index and valuation index. Net income increased 5.55% from -$9.74M to -$9.2M.
KemPharm, Inc. (KMPH) was upgraded to D from D- on 5/2/2016 due to an increase in the total return index, efficiency index and valuation index. Net income increased 5.55% from -$9.74M to -$9.2M.
D
Sell
1/4/2016Upgraded
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 1/4/2016 due to a noticeable increase in the growth index, valuation index and solvency index. Debt to equity declined from 5.46 to -3.83, and EBIT increased 8.8% from -$5.96M to -$6.48M.
KemPharm, Inc. (KMPH) was upgraded to D- from E+ on 1/4/2016 due to a noticeable increase in the growth index, valuation index and solvency index. Debt to equity declined from 5.46 to -3.83, and EBIT increased 8.8% from -$5.96M to -$6.48M.
E
Sell
10/1/2015Upgraded
KemPharm, Inc. (KMPH) was upgraded to E+ from E on 10/1/2015 due to a significant increase in the total return index, efficiency index and volatility index. Total capital increased 660.57% from $6.97M to $53.01M, and net income increased 397.87% from -$5.97M to -$29.74M.
KemPharm, Inc. (KMPH) was upgraded to E+ from E on 10/1/2015 due to a significant increase in the total return index, efficiency index and volatility index. Total capital increased 660.57% from $6.97M to $53.01M, and net income increased 397.87% from -$5.97M to -$29.74M.
E
Sell
7/10/2015None
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E from U on 07/10/2015.
Zevra Therapeutics, Inc. (ZVRA) was downgraded to E from U on 07/10/2015.
NASDAQ
03/14/2025 1:04PM Eastern
Quotes delayed
